Drug Manufacturer Interest In Rx-To-OTC Pipeline Growing – FDA’s Ganley
This article was originally published in The Tan Sheet
Executive Summary
FDA is seeing increased activity from drug companies wanting to switch their prescription drug products over-the-counter, according to Center for Drug Evaluation & Research OTC Drug Products Division Director Charles Ganley, MD
You may also be interested in...
Test Market/Actual Use Study Combination Proposed For Switch Candidates
Consumer purchasing and use of potential Rx-to-OTC switch drugs may be most accurately predicted by a combination of actual use studies with a form of test marketing, according to Bristol-Myers Squibb Executive Medical Director Carola Friedman, MD
Aspirin CVD Indication On OTC Labeling Urged By FDA’s Jenkins
A cardiovascular disease prevention indication on OTC aspirin could be on the horizon, particularly if industry heeds FDA's invitation to propose such a change to the internal analgesics monograph
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC